The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia

We examined the long-term clinical outcomes of patients with chronic myeloid leukemia (n = 41) receiving generic imatinib as first-line (n = 27) and second-line therapy (n = 14) in Bosnia and Herzegovina. Overall survival rates for first-line and second-line generic imatinib were 85% and 100%, respe...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia Vol. 17; no. 4; pp. 238 - 240
Main Authors:	Islamagic, Erna, Hasic, Azra, Kurtovic, Sabira, Suljovic Hadzimesic, Emina, Mehinovic, Lejla, Kozaric, Mirza, Kurtovic-Kozaric, Amina
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-04-2017
Subjects:	Adult Antineoplastic Agents - therapeutic use Bosnia and Herzegovina Clinical outcomes CML Drugs, Generic - therapeutic use Female Follow-Up Studies Glivec Humans Imatinib Mesylate - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Middle Aged Molecular response Retrospective Studies CML Glivec Bosnia and Herzegovina Molecular response Clinical outcomes
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!